首页> 外文期刊>Clinical microbiology and infection: European Society of Clinical Microbiology and Infectious Diseases >Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1) - Report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibili
【24h】

Antimicrobial susceptibility testing of Mycobacterium tuberculosis (EUCAST document E.DEF 8.1) - Report of the Subcommittee on Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis of the European Committee for Antimicrobial Susceptibili

机译:结核分枝杆菌的药敏试验(EUCAST E.DEF 8.1)-欧洲抗菌药物敏感性委员会结核分枝杆菌药敏试验小组委员会的报告

获取原文
获取原文并翻译 | 示例
       

摘要

This review describes the methods available for drug susceptibility testing of Mycobacterium tuberculosis. The methods have been developed over several decades and are restricted to specialised centres in most European countries, as they are technically demanding, require appropriate isolation facilities and can be difficult to interpret. The absolute concentration, resistance ratio and proportion methods can all give accurate results, provided that they are carefully quality-controlled and standardised. Automated rapid culture and molecular methods have been evaluated at large reference centres and in multicentre collaborations, and perform well for testing susceptibility to most first- and second-line anti-tuberculosis drugs. Accuracy is more important than rapid testing, and this is most reliably achieved if drug susceptibility tests are done in a small number of well-equipped, experienced laboratories that participate and perform well in an international drug susceptibility testing quality assessment scheme. The WHO Supranational Laboratory Quality Control Network offers a global scheme that assesses the ability of participating laboratories to identify isoniazid, rifampicin, ethambutol and streptomycin resistance. Second-line drug resistance testing is currently being standardised, and such testing should only be performed at the national reference laboratories in western and central European countries because of the relatively small number of cases and the concomitant difficulty of maintaining testing proficiency in multiple centres performing small numbers of tests. There is a need to expand international external quality assessment to include second-line drug susceptibility testing.
机译:这篇综述描述了可用于结核分枝杆菌药敏试验的方法。这些方法已经开发了数十年,并且由于技术上的要求,仅限于适当的隔离设施且可能难以解释,因此仅限于大多数欧洲国家的专门中心。绝对浓度,电阻比和比例方法都可以给出准确的结果,前提是它们必须经过严格的质量控制和标准化。自动化的快速培养和分子方法已在大型参考中心和多中心合作机构中进行了评估,在测试大多数一线和二线抗结核药物的敏感性方面表现良好。准确性比快速测试更重要,如果在少数设备完善,经验丰富的实验室中进行药物敏感性测试,而这些实验室参与并在国际药物敏感性测试质量评估方案中表现良好,则最可靠地实现这一目标。世界卫生组织超国家实验室质量控制网络提供了一个全球计划,该计划评估参与实验室鉴定异烟肼,利福平,乙胺丁醇和链霉素耐药性的能力。目前正在对二线抗药性测试进行标准化,并且由于病例数相对较少且在多个执行能力较弱的中心保持测试熟练度的同时困难,这种测试只能在西欧和中欧国家的国家参考实验室进行测试次数。有必要扩大国际外部质量评估以包括二线药物敏感性测试。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号